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Abstract 
 
Integrins regulate cellular adhesion and transmit signals important for cell survival, proliferation 
and motility. They are expressed by glioma cells and may contribute to their malignant 
phenotype. Integrin inhibition may therefore represent a promising therapeutic strategy. GL-261 
and SMA-560 glioma cells grown under standard conditions uniformly detached and formed 
large cell clusters after integrin gene silencing or pharmacological inhibition using EMD-121974, 
a synthetic Arg-Gly-Asp-motif peptide, or GLPG0187, a non-peptidic integrin inhibitor. After 
120 h, the clusters induced by integrin inhibition decayed and cells died. In contrast, when cells 
were cultured under stem cell (sphere) conditions, no disaggregation became apparent upon 
integrin inhibition, and cell death was not observed. Since Poly-HEMA-mediated detachment had 
similar effects on cell viability as integrin inhibition, we postulated that cell death may result 
from detachment alone which was confirmed using various permissive and non-permissive 
substrates. No surrogate markers of apoptosis were detected and electron microscopy confirmed 
that necrosis represents the dominant morphology of detachment-induced cell death. 
Additionally, integrin inhibition resulted in the induction of autophagy. When integrins were 
inhibited in non-sphere glioma cells, the TGF-β pathway was strongly impaired, whereas no such 
effect was observed in glioma cells cultured under sphere conditions. Cell death induced by 
integrin inhibition was rescued by addition of recombinant transforming growth factor-β (TGF-β) 
and accelerated by exposure to the TGF-β receptor inhibitor, SD-208. In summary, cell death 
following integrin inhibition is detachment-mediated, represents an atypical form of anoikis 
involving necrosis as well as autophagy, and is modulated by TGF-β pathway activity. 
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Introduction 
 
Integrins are a family of heterodimeric cell surface receptors formed by a combination of 18 α- 
and 8 β-subunits (1). Each subunit is a transmembrane protein with a large extracellular domain 
and a mostly short cytoplasmic domain, thus coordinating the assembly of cytoskeletal polymers 
and signaling complexes on the cytoplasmatic side of the cell membrane and an engagement of 
extracellular matrix (ECM) macromolecules or counter-receptors on the extracellular side (2). 
Integrins lack intrinsic catalytic activity, but by ECM-integrin interactions, signals are transduced 
into the cell through the activation of integrin-associated proteins and the establishment of focal 
adhesions (3, 4). Ligated integrins can activate pro-survival pathways by several mechanisms 
such as the induction of the phosphatidylinositol 3-kinase (PI3K)-AKT (5), NF-κB (6) and RAS-
RAF-MEK-ERK mitogen-activated protein kinase (MAPK) pathways (7) as well as the induction 
of BCL-2 (8) and FADD-like IL-1β-converting enzyme (FLICE)-inhibitory protein (FLIP) 
expression (9), and reduction of p53 activity (10). In contrast, unligated integrins expressed on 
adherent cells or antagonism of αvβ3 or β1 integrins can induce apoptosis (3, 11). Loss of ECM 
contact of adherent cells by disruption of integrin ligation promotes death by anoikis, and this 
form of cell death can be prevented by integrin-mediated adhesion (10-12). Anoikis is 
deregulated in various pathological conditions and anchorage-independent growth is a hallmark 
of tumorigenic transformation of cells favoring metastasis (10, 13).  
RGD integrins αvβ3, α5β1 and αvβ6 are frequently up-regulated in several tumor types and 
associated with inferior outcome (3, 14). In gliomas, the expression of integrins αvβ3, αvβ5 and 
αvβ8 increases with WHO grade of malignancy (15). 
Crosstalk between integrins and cytokines such as TGF-β is crucial for many aspects of tumor 
progression (3). TGF-β is a multipotent cytokine with important effects on glioma cell 
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proliferation, angiogenesis, invasion and immunity (16, 17). Integrins have been attributed an 
important role in the activation of TGF-β by liberating active TGF-β from the small latent 
complex (SLC) (18). Moreover, αv integrins appear to control TGF-β signaling in human glioma 
and glioma-initiating cell lines at the transcriptional level, too (15). In turn, TGF-β may promote 
glioma cell migration by the induction of αvβ3 integrin levels (19). Here, we characterized the 
mechanisms of cell death induced by integrin inhibition-mediated tumor cell detachment and its 
interaction with the TGF-β pathway in mouse glioma models. Given the proposed link between 
sphere culture conditions and stemness in glioma and other cancer paradigms in vitro (20, 21), 
most studies were performed in parallel under standard conditions and in sphere cultures. 
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Results 
 
Integrin inhibition induces detachment and death of mouse glioma cells: rescue by sphere culture 
conditions 
GL-261 and SMA-560 mouse glioma cells were cultured as adherent monolayer cultures under 
standard conditions or as sphere cultures. Adherent cells grown under standard conditions, 
referred to as non-sphere (NS) cells, detached after exposure to the integrin inhibitor cilengitide 
(Cil, EMD-121974), but not control peptide (RAD), and formed large cell clusters (Figure 1A, 
top, Supplementary Figure 1). After 120 h, the cilengitide-induced clusters disintegrated and 
there was wide-spread cell death confirmed by trypan blue dye exclusion (data not shown). In 
contrast, no morphological effects were observed when sphere cells (SC) were treated with 
cilengitide or RAD for up to 120 h (Figure 1A, bottom). The non-peptidic integrin antagonist 
GLPG0187 induced detachment and the formation of large cell aggregates in GL-261 and SMA-
560 NS cells, too. Again, no morphological changes were observed in the SC cultures after 
exposure to GLPG0187 (Figure 1B). αv gene silencing confirmed that detachment and induction 
of cell death were a specific effect of integrin inhibition (Figure 1C).  
The detachment of cilengitide-treated adherent cells was accompanied by a strong loss of 
metabolic activity as a surrogate marker of cell death in a time- and concentration-dependent 
manner as assessed by MTT assay. No such effect was observed in SC cultures (Figure 2A). This 
observation was not restricted to mouse cells since LN-18 human glioma cells, which were found 
to be most sensitive to detachment-induced cell death among a panel of human cell lines (22), 
acquired resistance to cilengitide when maintained as sphere cultures, too (Figure 2A). 
Accordingly, GLPG0187 dramatically reduced the viability of GL-261 NS and SMA-560 NS, but 
not of SC cultures (Figure 2B). Annexin V/PI staining confirmed the induction of cell death upon 
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integrin inhibition. Cilengitide-exposed NS cells displayed a high percentage of PI-positive cells, 
whereas no changes were observed in SC cultures (Figure 2C). Similarly, exposure to GLPG0187 
resulted in extensive cell death at concentrations as low as 1 nM within 24 h in GL-261 NS and 
SMA-560 NS, but not in GL-261 SC and SMA-560 SC (Figure 2D). The assumption that integrin 
inhibition mediates cell death of mouse NS was further confirmed by the observation of reduced 
glioma cell viability at 24 h after siRNA-mediated αv gene silencing (Figure 2E). Accordingly, 
NS glioma cells exposed to cilengitide lost membrane integrity as assessed by NHS-biotin 
staining (Supplementary Figure 2). 
 
The induction of cell death by integrin inhibition is detachment-mediated. 
There were no major differences in integrin mRNA levels between NS and SC (Figure 3A). 
However, exposure to cilengitide reduced v mRNA expression in NS, whereas only minor 
changes were observed in SC cells (Supplementary Figure 3A). Accordingly, cilengitide reduced 
αv cell surface protein levels in NS, but not in GL-261 SC and only to a lower extent in SMA-
560 SC (Figure 3B). Similarly, intracellular v protein levels were affected by cilengitide mainly 
in NS cells (Supplementary Figure 3B). This lack of effect in the SC cultures also confirmed that 
preexposure to cilengitide did not interfere with recognition of αv by the antibody used for flow 
cytometry.  
Poly-HEMA-mediated detachment, which operates by hydrogel formation, had similar effects on 
cell viability as exposure to cilengitide (Figure 3C), consistent with the notion that the anti-
adhesive effect of integrin inhibition is responsible for cell death observed in NS. Conversely, 
poly-HEMA conditions expectedly had no effect on SC formation (data not shown). Accordingly, 
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when GL-261 NS and SMA-560 NS were cultured on plates coated with collagens I or IV, which 
are not substrates for αv integrins, cilengitide neither detached nor killed the cells (Figure 3D,E).  
 
Integrin inhibition-induced cell death in mouse NS is caspase-independent. 
Neither increased caspase activity, assessed by DEVD-amc-cleavage (Figure 4A), nor increased 
caspase 3 processing on immunoblots (Figure 4B) was detected upon treatment with cilengitide. 
Furthermore, the pan-caspase inhibitor zVAD-fmk inhibited cell death induced by MFL or 
staurosporine (Stauro), but not by cilengitide (Figure 4C). Similarly, when glioma cells were 
engineered to stably express the caspase 1/8 inhibitor crm-A, MFL-induced caspase activity and 
cell death were blocked, but there was no rescue of integrin inhibition-mediated effects (Figure 
4D, top). Finally, crm-A reduced the percentage of annexin V-positive cells without increasing 
the overall number of double-negative, viable cells (Figure 4D, bottom), disclosing the exposure 
of annexin binding sites as caspase-dependent, but epiphenomenal to cell death induction. 
 
Integrin inhibitor-treated mouse glioma NS cells undergo necrosis. 
Next we investigated whether integrin inhibition induces autophagy in glioma cells. When SMA-
560 NS cells were exposed to 50 µM cilengitide, increased LC3A/B-II levels which are 
associated with the induction of autophagy were observed. Salinomycin was used as a positive 
control (Figure 5A). The administration of lower concentrations of cilengitide did not result in 
significant changes of LC3A/B-II protein levels. In GL-261 NS cells, higher constitutive 
LC3A/B-II levels were detected and no significant changes were observed upon cilengitide or 
salinomycin exposure (Figure 5A). Moreover, cilengitide induced the expression of the 
autophagy-related protein beclin-1 in a concentration-dependent manner in GL-261 NS and even 
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more in SMA-560 NS cells (Figure 5B). To further analyze the relevance of autophagy in 
integrin inhibition-mediated cell death, GL-261 NS and SMA-560 NS were stained with acridine 
orange for the detection of acidic vesicular organelles (AVO) or with monodansylcadaverine 
(MDC) for the detection of autophagic vacuoles, which are further hallmarks of autophagy. 
Compared to control cells, cilengitide-exposed NS of both cell lines showed increased AVO 
levels after 24 h even with cilengitide concentrations that did not induce LC3 A/B-II levels. 
Moreover, salinomycin, as in the LC3 A/B-II studies, induced signs of autophagy only in SMA-
560 cells (Figure 5C). Furthermore, compared to control cells, cilengitide-treated NS cells 
displayed an increase in MDC-positive vacuoles (Figure 5D). Next, we clarified whether 
autophagy is a survival signal or mediates cilengitide-induced cell death. To this end, glioma 
cells were cultured in the absence or presence of the autophagy inhibitor, 3-methyladenine (3-
MA). When autophagy was blocked by 3-MA, the amount of dead cells was increased, 
suggesting that autophagy in the context of integrin inhibition in murine NS cells represents a 
survival signal (Figure 5E). 
Finally, we examined the morphology of integrin inhibition-induced cell death using TEM. 
Cilengitide-exposed SMA-560 NS cells were characterized by binding to each other, visible as 
dark adhesion sites along the cell membrane and necrosis-like cell debris between the cells, but 
no signs of apoptosis, such as crescent dark DNA along the nuclear membrane or dark cytoplasm, 
as observed with staurosporine, were noticed. Salinomycin-treated samples showed classical 
signs of autophagy such as mitochondria with swollen matrix, swollen endoplasmatic reticulum 
and an increased frequency of autophagosomes, thus characteristics not observed upon cilengitide 
exposure, indicating that cell death upon integrin inhibition in NS cells is essentially a necrotic 
process (Figure 6A). Indeed, SMA-560 SC became apparent as loose cell agglomeration with 
some dead cells inside the spheroid, but no major differences were observed between cells 
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exposed to cilengitide or control peptide and extensive cell death was noticed only as a result of 
staurosporine treatment (Supplementary Figure 4). To distinguish necroptosis, the programmed 
form of necrosis, from the morphologically identical but unregulated form of necrosis, we 
blocked necroptosis with the receptor interacting protein (RIP)1 inhibitor necrostatin-1 (Nec-1). 
Exposure to Nec-1 significantly attenuated the effect of cilengitide in murine GL-261 and SMA-
560 NS as well as in human LN-18 NS cells, indicating that necroptosis contributes to integrin 
inhibition-induced cell death (Figure 6B). 
TGF-β2 protects from cell death induced by integrin inhibition.  
We explored whether integrin inhibition interferes with TGF-β signaling in mouse glioma cells, 
too (15). Cilengitide reduced Smad2 phosphorylation in GL-261 NS and SMA-560 NS, but not 
SC cells (Figure 7A). Similarly, exposure to GLPG0187 resulted in decreased pSmad2 levels in 
GL-261 NS and SMA-560 NS, but not in SC cultures (Figure 7B). To analyze whether these 
reductions of pSmad2 levels in NS cells result from detachment than integrin inhibition, NS cells 
were again cultured on cell culture plates coated with collagen I to prevent detachment. Still, 
integrin inhibition resulted in reduced pSmad2 levels, albeit to a much lower extent, suggesting 
that impaired TGF-β signaling results from both integrin inhibition and detachment in this model 
(Supplementary Figure 5). Since integrin inhibition reduced pSmad2 levels only in GL-261 NS 
and SMA-560 NS cells, we asked whether reduced TGF-β signaling was linked to integrin 
inhibition-induced detachment and cell death. Addition of exogenous recombinant TGF-β2 to 
cilengitide-treated cells had no effect on detachment, and exposure to the TGF-β receptor kinase 
inhibitor SD-208 did not induce detachment or cell death (data not shown). However, the 
addition of recombinant TGF-β attenuated cilengitide-induced cell death in a concentration-
dependent manner (Figure 7C,D), and TGF-β-induced modulation of cilengitide-induced cell 
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death was blocked by co-exposure to SD-208 (Figure 7C). In fact, the extent of cell death was 
even more prominent when cilengitide-treated cells were co-exposed to SD-208 (Figure 7E). 
Finally, we evaluated whether TGF-β2 modulates integrin expression of GL-261 and SMA-560 
NS. αv integrin levels were decreased by cilengitide and increased by exogenous TGF-β2 in a 
concentration-dependent manner. No significant change was induced by SD-208 (Figure 7F). 
These results indicate that TGF-β-mediated upregulation of integrin expression might activate 
pro-survival pathways, which may be involved in the counteraction of integrin inhibition-
mediated cell death. To analyze whether TGF-β2-mediated prevention is a specific effect in 
integrin inhibition-induced cell death, cells were exposed to a combination of increasing 
concentrations of staurosporine which induces apoptotic cell death or temozolomide, an 
alkylating agent used for the treatment of glioblastoma patients, and TGF-β2. Only very high 
concentrations of temozolomide were active in these assays, and no rescue effect of TGF-β2 was 
observed (Supplementary Figure 6A, B).  
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Discussion 
 
Integrins are crucial for many aspects of tumor biology including tumor initiation, progression 
and metastasis of solid tumors, making them an appealing target for cancer therapy (3). Various 
integrin antagonists have been developed for antitumor therapy and several of them are in late-
stage clinical development, all of them targeting RGD-binding integrins (23). Despite some 
clinical drawbacks in the development of pharmacological inhibitors, integrins remain a 
promising target for anti-cancer therapy due to their action as regulators of various processes in 
tumor and tumor-associated host cells. 
Inhibition of integrin signaling had variable effects on cell viability in glioma cells (22, 24, 25). 
In the mouse glioma model systems used here, we noticed extensive cell death following integrin 
inhibition in all 4 mouse glioma cell lines tested when cultured as adherent cells, that is, under 
standard conditions, whereas no such effect became apparent when the same cells where cultured 
under sphere conditions (Figure 1) which we had explored as a possible in vitro model of 
stemness (26). Similarly, also in human LN-18 glioma cells, integrin inhibition-induced cell 
death was only observed when the cells were cultured under standard adherent conditions, but not 
when cultured as spheres (Figure 2A). We confirmed that cell death triggered by blocking 
integrins is a consequence of detachment since integrin inhibition in cells maintained on collagen, 
which is not a ligand for αv integrins, neither affected attachment nor viability (Figure 3D,E).  
Interestingly, the sphere culture controls that we included demonstrate that glioma cells may well 
survive in non-adherent culture systems and acquire a phenotype that induces non-responsiveness 
to the signaling cascades of integrin-mediated cell death as well as to integrin control of the TGF-
β pathway. Elucidating why sphere cultures are resistant to integrin inhibition is an interesting 
question that is beyond the scope of the present work. Unpublished work from our laboratory 
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shows that simply transferring mouse glioma cells into sphere cultures does not make these cells 
uniformly stem-like by current criteria of stemness (Ahmad et al. submitted for publication). 
Most cells undergo cell death upon integrin inhibition-mediated detachment, a process called 
anoikis (27, 28). Anoikis has previously been described essentially as an apoptotic process (13). 
It has been reported that endothelial cells as well as human glioma cell lines undergo detachment 
and apoptosis upon integrin inhibition with cilengitide (25). However, upon integrin inhibition, 
we did not observe any signs of apoptosis. The cells neither displayed increased DEVD-amc-
cleaving caspase activity nor increased caspase 3 processing. Furthermore, addition of the pan-
caspase inhibitor zVAD-fmk or expression of the caspase 1/8 inhibitor crm-A did not rescue 
integrin inhibition-induced cell death (Figure 4). Finally, electron microscopy ruled out necrosis 
as the principal mode of cell death after integrin inhibition (Figure 6A). The induction of necrosis 
involved necroptosis, the programmed form of necrosis (Figure 6B). 
Autophagy has been proposed as a primary effector mechanism of anoikis, and autophagy may 
also represent an execution backup to apoptosis in apoptosis-resistant cells (29). Human glioma 
cells have been reported to undergo autophagy upon integrin inhibition with cilengitide at 
concentrations of 25 mg/ml, corresponding to 44 µM (24). In our cell models, autophagy was 
inducible upon integrin inhibition with 50 µM cilengitide. However, this is apparently not the 
mechanism responsible for cell death in these cells since a major loss of viability was observed 
with cilengitide concentrations as low as 100 nM (Figure 2) and moreover, inhibition of 
autophagy even increased the extent of cell death (Figure 5E). Accordingly, autophagy has been 
described as a pro-survival mechanism through suppression of necrotic cell death (30). 
Furthermore, it has been reported that autophagy may promote cell survival particularly in the 
context of anoikis (31, 32). 
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Recently, we have shown that inhibition of integrin signaling using various approaches reduces 
TGF-β expression and TGF-β signaling in human glioma cell lines (15). Thus, we were interested 
to explore whether this mechanism may be involved in detachment-induced cell death. Blocking 
integrin function with cilengitide or GLPG0187 reduced TGF-β signaling in adherent murine 
glioma cells, whereas no such effect became apparent in sphere cells (Figure 7A,B). When 
adherent GL-261 and SMA-560 cells were cultured on plates coated with collagen which is not a 
substrate for αv integrins, pSmad2 reductions were observed upon integrin inhibition, even 
without detachment, however, to a much lower extent than under conditions of detachment 
(Supplementary Figure 5). These data suggest that impaired TGF-β signaling upon integrin 
inhibition results from both integrin inhibition and detachment. Indeed, because of very rapid 
detachment of adherent murine glioma cells upon integrin inhibition at lowest concentration, a 
separate analysis of attached and detached cell fractions was technically not possible. These data 
prompted us to investigate whether impaired TGF-β signaling is linked to the induction of cell 
death in adherent cells upon integrin inhibition. Indeed, cell death was partially rescued by 
exogenous TGF-β2, in a SD-208-sensitive manner (Figure 7C,D). Previously, exposure of human 
glioma cells to TGF-β has been shown to induce integrin αvβ3 expression, an effect that was 
postulated to promote migration (19). Here, TGF-β enhanced survival of mouse glioma cells 
without promoting attachment, indicating that TGF-β can promote survival down-stream of 
integrin signaling under a stress condition such as anoikis. Integrin αvβ3 expression in carcinoma 
cells was linked to enhanced anchorage-independent tumor growth and increased lymph node 
metastases by activation of c-Src and phosphorylation of Crk-associated substrate (CAS), 
resulting in tumor cell survival independent of cell adhesion (33). In addition, TGF-β may induce 
the activation of pro-survival pathways such as MAPK (34, 35) and PI3K (36), pathways 
implicated in adhesion-regulated cell survival, too (10). Our results may therefore point to a 
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novel mode of anoikis in the absence of apoptosis, but related to necrosis partially controlled by 
the TGF- pathway in glioma cells. 
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Materials and methods 
 
Cells and reagents 
The human glioma cell line LN-18 was provided by N. de Tribolet (Lausanne, Switzerland). 
Mouse SMA-497, SMA-540 and SMA-560 glioma cells were provided by D. Bigner (Durham, 
DC) and GL-261 cells by X.O. Breakefield (Boston, MA). The cells were cultured in Dulbecco's 
Modified Eagle Medium (DMEM; Invitrogen, Basel, Switzerland), containing 2 mM L-glutamine 
(Gibco Life Technologies, Paisley, UK), and 10% fetal calf serum (FCS; PAA, Vienna, Austria) 
(standard conditions, non-sphere, NS) or in Neurobasal Medium with B-27 supplement (20 
µl/ml) and Glutamax (10 µl/ml) from Invitrogen and fibroblast growth factor (FGF)-2, epidermal 
growth factor (EGF) (20 ng/ml each; Peprotech, Rocky Hill, PA) and heparin (32 IE/ml; 
Ratiopharm, Ulm, Germany) (sphere conditions, SC). Accutase was obtained from PAA. 
Cilengitide (EMD 121974) was kindly provided by Merck KGaA (Darmstadt, Germany) and 
GLPG0187 was kindly supplied by Galapagos NV (Mechelen, Belgium). The RAD peptide 
cyclo-(Arg-Ala-Asp-DPhe-Val) was purchased from Bachem AG (Bubendorf, Switzerland). The 
following antibodies were used for immunoblot analysis: goat polyclonal antibody to actin and 
beclin-1 antibody were obtained from Santa Cruz Biotechnology (Santa Cruz, CA), phospho-
Smad2 antibody (Ser465/467) (clone 138D4), phospho-AKT antibody, caspase-3 antibody and 
LC3A/B antibodies were purchased from Cell Signaling Technology (Boston, MA) and crm-A 
antibody from BD Biosciences (Franklin Lakes, NJ). Recombinant human TGF-2 was purchased 
from PeproTech. The TGF-β receptor I kinase inhibitor SD-208 was provided by Scios Inc. 
(Fremont, CA). zVAD-fmk was purchased from Tocris Bioscience (Bristol, UK), 3-
methyladenine (3-MA) from Sigma-Aldrich (St. Louis, MO) and necrostatin-1 (Nec-1) from 
Merck KGaA. Staurosporine was from AppliChem (Darmstadt, Germany), annexin V from BD 
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Biosciences and propidium iodide (PI) was from Sigma-Aldrich. Cell culture dishes coated with 
fibronectin (FN), laminin (Lam), collagen I (Col I) or collagen IV (Col IV) were purchased from 
BD Biosciences. Poly(2-hydroxyethyl methacrylate) (Poly-HEMA) was purchased from Sigma-
Aldrich. The siRNA pool targeting integrin αv (ON-TARGETplus SMARTpool) and the non-
targeting control pool (ON-TARGETplus siCONTROL) were purchased from Thermo Scientific 
Dharmacon (Lafayette, CO) and used at 100 nM. The duplex sense sequences of the siRNA pool 
targeting αv were: 5`-GCGCAAUCCUGUACGUGAA-3`, 5`-CCAAUUAGCAACACGGACU-
3`, 5`-GUGAGGAACUGGUCGCCUA-3` and 5`-GUGAACAGAUGGCUGCGUA-3`. Stable 
cytokine response modifier A (crm-A) transfectants were obtained using the pEFR crm-A 
plasmid (37) and subsequent puromycin selection (10 µg/ml). Stable and transient lipophilic 
transfection was performed with Metafectene Pro (Biontex, Martinsried, Germany).  
 
Real-time PCR 
Total RNA was isolated using the NucleoSpin RNA II system from Macherey-Nagel (Düren, 
Germany) and cDNA was prepared using the iScript cDNA Synthesis Kit from Bio-Rad 
Laboratories AG (Cressier, France). For real-time PCR, gene expression was measured in an ABI 
Prism 7000 Sequence Detection System (Applied Biosystems, Foster City, CA) with SYBR 
Green Master Mix (Thermo Fisher Scientific, Waltham, MA) and primers (Microsynth AG, 
Balgach Switzerland) at optimized concentrations. The sequences were as follows: 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), forward 5'-
AGGTCGGTGTGAACGGATTTG-3' (NM_008084, 8-28 nt), reverse 5'-
TGTAGACCATGTAGTTGAGGTCA-3' (NM_008084, 130-108 nt), αv, forward 5'-
AAAGACCGTTGAGTATGCTCCA-3' (NM_008402, nt 492-513), reverse 5'-
ATGCTGAATCCTCCTTGACAAAA-3' (NM_008402, nt 572-550), α5, forward 5'-
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CTTCTCCGTGGAGTTTTACCG-3' (NM_010577, nt 192-212), reverse 5'-
GCTGTCAAATTGAATGGTGGTG-3' (NM_010577, nt 354-333), β1, forward 5'- 
ATGCCAAATCTTGCGGAGAAT-3' (NM_010578, nt 92-112), reverse 5'- 
TTTGCTGCGATTGGTGACATT-3' (NM_010578, nt 300-280), β3, forward 5'-
GGCGTTGTTGTTGGAGAGTC-3' (NM_016780, nt 61-80), reverse 5'-
CTTCAGGTTACATCGGGGTGA-3' (NM_016780, nt 198-178), β5, forward 5'- 
GAAGTGCCACCTCGTGTGAA-3' (NM_001145884, nt 92-111), reverse 5'- 
GGACCGTGGATTGCCAAAGT-3' (NM_001145884, nt 177-158) and β8, forward 5'- 
TGGCCCTTTATTCCCGTGAC-3' (NM_177290, nt 530-549), reverse 5'-
GGGTGGATACTAATGTATGGCGA-3' (NM_177290, nt 611-589).  The conditions were 40 
cycles at 95°C/15 s and 60°C/1 min. Standard curves were generated for each gene. Relative 
quantification of gene expression was determined by comparison of threshold values. All results 
were normalized to GAPDH and calculated with the ΔCTT method for relative quantification 
(38). 
 
Immunoblot analysis 
For the detection of proteins from cell lysates, cells were lysed in radioimmunoprecipitation 
assay (RIPA) buffer (10 mM Tris pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% deoxycholate, 0.1% 
sodium dodecyl sulfate) supplemented with 1x complete inhibitor mix (Roche Diagnostics, 
Grenzach-Wyhlen, Germany) and phosphatase inhibitor cocktails 1 and 2 (Sigma-Aldrich, St. 
Louis, MO). Protein levels were analyzed
 
by immunoblot using 20 µg of protein per lane mixed 
with Laemmli buffer containing β-mercaptoethanol. Equal protein loading was ascertained by 
Ponceau S staining.
 
Visualization
 
of protein bands was accomplished using horseradish 
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peroxidase
 
(HRP)-coupled secondary antibodies (Sigma-Aldrich)
 
and enhanced 
chemiluminescence (Perbio, Bonn, Germany). 
 
Flow cytometry 
For detection of αv cell surface protein levels, cells were detached with accutase, incubated with 
primary antibody anti-αv (Biolegend, San Diego, CA) or isotype control, followed by exposure to 
fluorescein isothiocyanate (FITC)-conjugated secondary antibody anti-rat IgG conjugate (Sigma 
Aldrich), diluted in PBS containing 0.5% bovine serum albumin, 2 mM EDTA and 1 mM MgCl2. 
For detection of intracellular αv protein levels, cells were permeabilized using the Fix/Perm 
Buffer Set (Biolegend) prior to αv staining. Cell surface or intracellular expression levels were 
determined using a CyAn flow cytometer.  
For the detection of acidic vesicular organelles (AVO), the cells were removed from the plate 
with accutase and stained with acridine orange (Sigma-Aldrich) at a final concentration of 1 
µg/ml. Green (510 - 530 nm, FITC) and red (>650 nm, phycoerythrin (PE)) excitation light was 
measured with a CyAn flow cytometer (39). For analysis of cell death, cells were treated as 
indicated, incubated with FITC-labeled AnxV-fluorescein isothiocyanate and PI for 30 min, and 
fluorescence was recorded in a CyAn flow cytometer. AnxV-fluorescein isothiocyanate- or PI-
positive cells were counted as dead cells (either apoptotic or necrotic), and the remaining cells 
were designated the surviving cell fraction. 
 
Caspase activity assay 
Caspase activity was assessed using the fluorescent substrate DEVD-amc (Bachem AG) and a 
Mithras microplate reader (Berthold Technologies, Bad Wildbad, Germany). Cells were kept in 
19 
 
phenol red-free medium containing the different compounds as indicated (40). Subsequently, 
cells were lysed and exposed to 12.5 µM DEVD-amc for 1 h. 
 
MTT assay 
For cytotoxicity assays, 10
4
 cells per well were seeded in 96-well plates, allowed to attach for 24 
h and subsequently exposed to different compounds as indicated in serum-free medium. For 
clonogenic assays, 10
2
 cells per well were seeded in 96-well plates, allowed to attach for 24 h and 
subsequently exposed to different compounds as indicated for 24 h in serum-free medium, 
followed by observation for 7-14 days in serum-containing medium.  For both assays, metabolic 
activity as a surrogate marker of viability was assessed using MTT.  
 
NHS-Biotin staining 
Cells were detached using accutase, incubated with 0.1 mg/ml NHS-Biotin 
(AppliChem,Darmstadt, Germany) for 30 min on ice, fixed in PBS containing 3% 
paraformaldehyde and 2% sucrose and subsequently cytospun onto glass slides. For visualization, 
Cy3-conjugated streptavidin (Biolegend) was applied. Samples were mounted in Vectashield 
Mounting Media with DAPI (Burlingame, CA).  
 
Monodansylcadaverine (MDC) staining 
Cells were detached using accutase, incubated with 50 µM MDC (Sigma-Aldrich) for 10 min at 
37°C, fixed in PBS containing 2% paraformaldehyde, cytospun onto glass slides and analyzed by 
fluorescence microscopy. The presence of cells on the glass slides was approved by DAPI 
staining in parallel. 
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Transmission electron microscopy (TEM) 
Cells treated as indicated were fixed in 2.5% glutaraldehyde in 100 mM sodium cacodylate 
buffer, pH 7.4, dehydrated in a graded ethanol series after OsO4 fixation and embedded into epon 
(Catalyst). Sections of 60 nm were imaged with a Tecnai Spirit transmission electron microscope 
(FEI, Hillsborough, OR). 
 
Statistical analysis 
Data are presented as means and SD. The experiments shown were commonly repeated three 
times. Representative experiments are shown for some studies. Analysis of significance was 
performed using a two-tailed Student’s t-test (Excel, Microsoft, Redmond, WA) (*p<0.05, 
**p<0.01). 
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Figure legends 
 
Figure 1. Integrin inhibition induces detachment of mouse NS cells. A. GL-261 or SMA-560 
cells cultured under standard (NS) or sphere (SC) conditions were seeded at 200`000 cells/well 
and, after 24 h, exposed to control peptide (RAD) or cilengitide (10 µM) (scale bar, 100 µm). B. 
GL-261 (left) or SMA-560 (right) NS or SC were exposed to DMSO control or GLPG0187 (1 
nM) for 24 h (scale bar, 100 µm). C. GL-261 NS (top) or SMA-560 NS (bottom) were transfected 
with control or αv intergrin siRNA. Gene silencing was quantified after 24 h by flow cytometry 
and is expressed as SFI (left). The reduction of expression levels relative to control transfectants 
is indicated (middle). The transfected cells were monitored for attachment for 24 h (right, scale 
bar, 200 µm). 
 
Figure 2. Sphere formation protects from cell death induced by v integrin inhibition. A. 
GL-261, SMA-560, SMA-497, SMA-540 or LN-18 glioma NS or SC were exposed to RAD (10 
µM) or increasing concentrations of cilengitide as indicated for 24, 48 or 72 h. Metabolic activity 
was assessed by MTT assay and is indicated relative to RAD-treated cells. B. GL-261 or SMA-
560 NS or SC were exposed to DMSO or increasing concentrations of GLPG0187 as indicated 
for 24, 48 or 72 h. Metabolic activity was assessed by MTT assay and is indicated relative to 
control-treated cells. C. SMA-560 or GL-261 NS or SC were exposed to RAD or cilengitide (10 
µM) for 48 h. Cell death was assessed by annexin V/PI staining. D. SMA-560 and GL-261 NS or 
SC were exposed to GLPG0187 (1 nM) or DMSO control for 48 h and analyzed for cell death by 
annexin V/PI staining. E. GL-261 (top) and SMA-560 (bottom) control and αv knock-down 
transfectants were analyzed for cell death 24 h after transfection by annexin V/PI staining. 
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Figure 3. The induction of cell death caused by integrin inhibition is detachment-mediated. 
A. Integrin mRNA levels were assessed by real-time PCR in GL-261 or SMA-560 NS or SC. B. 
αv protein levels were assessed by flow cytometry in NS or SC exposed to RAD or cilengitide 
(10 µM) for 24 h. C. GL-261 NS or SMA-560 NS were exposed to RAD or cilengitide (10 µM) 
or cultured on cell culture dishes pre-treated with poly-HEMA (12 mg/ml) for 48 h. Cell death 
was assessed by annexin V/PI staining. D. GL-261 NS or SMA-560 NS cultured on plates coated 
with collagen I or collagen IV or poly-D-lysine (control) were allowed to attach for 24 h. 
Subsequently, the cells were exposed to RAD or cilengitide (10 µM) for 48 h and monitored for 
attachment (scale bar, 100 µm). E. Viability of cells treated as in (D) was examined by annexin 
V/PI staining. 
 
Figure 4. Integrin inhibition-induced cell death in mouse NS does not require caspase 
activity. A. GL-261 NS (left) or SMA-560 NS (right) were exposed to RAD, cilengitide (1 or 10 
µM), MFL (50 ng/ml), staurosporine (50 nM), zVAD-fmk (10 µM), or combinations thereof for 
6 h. DEVD-amc cleaving activity was determined fluorometrically. B. Whole cell protein lysates 
of GL-261 NS or SMA-560 NS exposed to RAD, cilengitide (1 or 10 µM) or staurosporine (50 
nM) for 24 h were assessed for full-length and cleaved caspase-3, using actin as a loading 
control. C. GL-261 NS or SMA-560 NS were exposed to RAD, cilengitide (10 µM), zVAD-fmk 
(1 µM), staurosporine (50 nM) or to a combination of zVAD-fmk (1 µM) and cilengitide (10 
µM) or staurosporine (50 nM). Viability was assessed after 24 h treatment by annexin V/PI 
staining. D. Control or crm-A transfectants were exposed to RAD, cilengitide (10 µM) or MFL 
(50 ng/ml) for 6 h and analyzed for DEVD-amc cleaving caspase activity (top). Cell death was 
assessed by annexin V/PI staining after exposure to RAD or cilengitide (10 µM) for 24 h 
(bottom). 
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Figure 5. Cilengitide-treated mouse glioma NS show signs of autophagy. A,B. Whole cell 
protein lysates of GL-261 NS and SMA-560 NS exposed to RAD, cilengitide (10 or 50 µM) or 
salinomycin (4 µM) for 24 h were analyzed for LC3A/B (A) or beclin-1 (B) using actin as a 
loading control. C. GL-261 or SMA-560 NS were exposed to RAD, cilengitide (10 or 50 µM) or 
salinomycin (4 µM) for 24 h. The development of AVO was assessed by acridine orange 
staining. D. GL-261 or SMA-560 NS were exposed to RAD or cilengitide (10 µM) for 24 h. 
Autophagic vacuoles were stained with MDC (green; nucleus, blue). E. GL-261 or SMA-560 NS 
were treated with 3-MA (1 mM) for 60 min followed by RAD or cilengitide (10 or 50 µM) for 48 
h. Metabolic activity was assessed by MTT assay and is indicated relative to RAD-treated cells. 
 
Figure 6. Cilengitide-treated mouse glioma NS cells undergo necrosis. A. SMA-560 NS were 
exposed to RAD, cilengitide (10 µM), staurosporine (1 µM) or salinomycin (5 µM) as indicated 
for 48 h and monitored by TEM. Images in the right column of each panel show a magnified part 
of the images on the left. Cells binding to each other are indicated with blue arrows, blue stars 
point to necrosis-like cell debris, blue arrowheads to crescent DNA along the nucleus, red arrows 
to swollen mitochondria and red arrowheads to autophagosomes (scale bar, 2 µm). B. GL-261 or 
SMA-560 NS were treated with Nec-1 (100 µM) for 60 min followed by increasing 
concentrations of cilengitide as indicated for 72 h. Metabolic activity was assessed by MTT assay 
and is indicated relative to control cells not pre-exposed to Nec-1. 
 
Figure 7. TGF-β2 counteracts integrin inhibition-induced cell death. A,B. GL-261 (left) or 
SMA-560 (right) NS or SC were exposed to RAD or cilengitide (10 µM) (A). GL-261 (left) or 
SMA-560 (right) NS or SC were exposed to DMSO or GLPG0187 (1 nM) (B). Subsequently, 
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whole cell protein lysates were assessed for pSmad2 levels by immunoblot, using actin as a 
loading control. C. GL-261 NS or SMA-560 NS were exposed to combinations of cilengitide and 
TGF-β2 as indicated with or without SD-208 (1 µM). Metabolic activity was assessed using MTT 
assay. D. GL-261 NS or SMA-560 NS were exposed to RAD, cilengitide (10 µM), TGF-β2 (10 
ng/ml) or a combination of cilengitide (10 µM) and increasing concentrations of TGF-β2 as 
indicated for 48 h. Viability was assessed by annexin V/PI staining. E. GL-261 NS or SMA-560 
NS were exposed to RAD, cilengitide (10 µM), SD-208 (1 µM) or a combination of cilengitide 
(10 µM) and SD-208 (1 µM) for 48 h. Cell viability was assessed by annexinV/PI staining. F. αv 
protein levels were assessed by flow cytometry in GL-261 NS or SMA-560 NS exposed to RAD 
(10 µM), cilengitide (1 or 10 µM), TGF-β2 (1 or 10 ng/ml) or SD-208 (1 µM) for 48 h. 
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Supplementary Figure legends 
 
Supplementary Figure 1. Integrin inhibition induces detachment of adherent mouse glioma 
cells. GL-261 NS or SMA-560 NS were exposed to cilengitide (10 µM) and monitored for 
detachment over a period of 6 h. 
 
Supplementary Figure 2. Integrin inhibition induces loss of membrane integrity in mouse 
NS. GL-261 or SMA-560 NS were exposed to RAD or cilengitide (10 µM). After 24 h, 
membrane integrity was examined using N-hydroxysuccinimidyl biotin (NHS-Biotin) labeling 
(red; nucleus, blue). 
 
Supplementary Figure 3. Reduced αv cell surface protein levels upon integrin inhibition 
results from reduced αv mRNA levels in mouse NS. A. GL-261 or SMA-560 NS or SC were 
exposed to RAD or cilengitide (10 µM) for 24 h and αv mRNA levels were assessed by real-time 
PCR. B. GL-261 or SMA-560 NS or SC were exposed to RAD or cilengitide (10 µM) for 24 h. 
Upon permeabilization of the cell membrane, intracellular αv protein levels were analyzed by 
flow cytometry. 
 
Supplementary Figure 4. Integrin inhibition does not affect viability of mouse SC. SMA-560 
SC were exposed to RAD, cilengitide (10 µM) or staurosporine (1 µM) as indicated for 48 h and 
analyzed by TEM. Blue arrowheads point to crescent DNA along the nucleus (scale bar, 2 µm). 
 
Supplementary Figure 5. Reduced Smad2 phosphorylation upon integrin inhibition is not 
restricted to detached cells. A. GL-261 or SMA-560 NS seeded on cell culture dishes coated 
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with collagen I were allowed to attach for 24 h. Subsequently, the cells were exposed to RAD or 
cilengitide (1 or 10 µM) (left) or DMSO or GLPG1087 (1 or 100 nM) (right) for 48 h. Whole cell 
lysates of these cells were analyzed for pSmad2 levels by immunoblot using actin as a loading 
control.  
 
Supplementary Figure 6. Staurosporine or temozolomide (TMZ)-induced cell death in 
mouse NS is not rescued by TGF-β2. A,B. GL-261 NS (top) or SMA-560 NS (bottom) were 
exposed to combinations of staurosporine [acute growth inhibition assay (A)] or TMZ 
[clonogenic cell death assay (B)] and TGF-β2 as indicated for 48 h or 24 h, respectively. 
Metabolic activity was assessed using MTT assay. 
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